---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-003608"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2022-02-02T23:59:59+00:00"
generated_at: "2026-06-27T12:40:35.630974+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q1 net loss widens to $0.60/share; GSK licenses NASH candidate

## Summary
- Net loss of $62.9M ($0.60 diluted EPS) vs $20.7M ($0.20) in prior year quarter.
- Revenue rose to $27.4M from $21.3M, primarily from license and collaboration revenue.
- R&D expense nearly doubled to $65.8M; G&A expense tripled to $25.0M.
- Initiated PALISADE Phase 3 study for ARO-APOC3 in familial chylomicronemia syndrome.
- Entered exclusive license with GSK for ARO-HSD (NASH); advanced two pulmonary candidates.

## SEC filing metadata
- accession: 0001564590-22-003608
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2022-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000156459022003608/0001564590-22-003608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000156459022003608/arwr-8k_20220202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-003608
- JSON: https://secwatch.observer/filing/0001564590-22-003608.json
- Plain text: https://secwatch.observer/filing/0001564590-22-003608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.